Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHCY | P23526 | 15/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.34 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.33 |
| ▸ | PI4KA | P42356 | 2/20 | 0.33 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.33 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.33 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.33 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13458411 | 0.90 | AHCY (0.55) | AHCYADORA2AADORA3ADORA1PI4KA | |
| SCHEMBL12633450 | 0.79 | AHCY (0.55) | AHCYADORA2AADORA3ADORA1PI4KA | |
| SCHEMBL12634623 | 0.79 | AHCY (0.55) | AHCYADORA2AADORA3ADORA1PI4KA | |
| SCHEMBL2026537 | 0.78 | AHCY (0.48) | AHCY | |
| SCHEMBL13458410 | 0.75 | AHCY (0.50) | AHCY | |
| SCHEMBL13457933 | 0.73 | AHCY (0.59) | AHCYADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL1934441 | 0.72 | ADORA2A (0.63) | AHCYADORA2AADORA3ADORA1PI4KA | |
| SCHEMBL12280365 | 0.72 | ADORA2A (0.63) | AHCYADORA2AADORA3ADORA1PI4KA | |
| SCHEMBL12573420 | 0.72 | AHCY (0.81) | AHCY | |
| SCHEMBL12573439 | 0.71 | AHCY (0.80) | AHCY |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010027935-A1 | AHCY HYDROLASE INHIBITORS FOR TREATMENT OF HYPER HOMOCYSTEINEMIA | MERCK SHARP & DOHME CORP. (US) | 2010-03-11 | — | — | WO | disclosed |